Non-contraceptive benefits of oral hormonal contraceptives

International Journal of Endocrinology and Metabolism

Volumn 11, Issue 1, 2013, Pages 41-47

  Schindler, Adolf E ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Contraceptives; Hormonal; Oral; Prevention and control; Therapeutics

Indexed keywords

CHLORMADINONE ACETATE; CYPROTERONE ACETATE; DIENOGEST; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ACNE; ADENOMYOSIS; ALOPECIA; ARTICLE; ASTHMA; BLEEDING DISORDER; BONE DENSITY; BONE STRUCTURE; BREAST FIBROADENOMA; CANCER PREVENTION; CLINICAL EFFECTIVENESS; COLON CANCER; DISEASE ASSOCIATION; DYSMENORRHEA; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FIBROCYSTIC BREAST DISEASE; HIRSUTISM; HUMAN; MENSTRUAL MIGRAINE; MENSTRUATION; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYOMA; OVARY CANCER; OVARY CYST; OVARY POLYCYSTIC DISEASE; PELVIC INFLAMMATORY DISEASE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; RECTUM CANCER; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SEBORRHEA; SPEECH DISORDER; VIRILIZATION;

EID: 84872789643     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.4158     Document Type: Article

References (53)

1. Fraser IS. Non-contraceptive health benefits of intrauterine hormonal systems. Contraception. 2010;82(5):396-403.
2. Asbell B. The pill: a biography of the drug that changed the world. Random House New York. 1995.
3. Kaunitz AM. Oral contraceptive health benefits: perception versus reality. Contraception. 1999;59(1 Suppl):29S-33S.
4. Jensen JT. The befits of reduced menstrual bleeding associated with the use of contraceptive methods. Gynecol Forum. 2010;15():10-4.
5. Fraser IS, Porte RJ, Kouides PA, Lukes AS. A benefit-risk review of systemic haemostatic agents: part 1: in major surgery. Drug Saf. 2008;31(3):217-30.
6. Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care. 2008;13(1):17-24.
7. Schindler AE. Non-contraceptive use of hormonal contraceptives for women with various medical problems. J PediaA.E. Non-contt Obstet Gynecol. 2008;34():183-200.
8. Schindler AE. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. Eur J Obstet Gynecol Reprod Biol. 2004;112():136-41.
9. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod. 2001;16(1):36-42.
10. Venturoli S, Paradisi R, Saviotti E, Porcu E, Fabbsi R, Orsini LF. Ulrtasouns study of ovarian and uterine morphology in women with PCOS before, during and after treatment with CPA and EE. Arch Gynecol. 1987;237():1-10.
11. Schindler AE, Mangold K, Friedrich E, Keller E, Göser R. Therapy of androgenetic symptomatology with cyproterone acetate and ethinyl estradiol. Arch Gyn Obst. 1978;225(2):103-7.
12. Huber JC, Bentz EK, Ott J, Tempfer CB. Non-contraceptive benefits of oral contraceptives. Expert Opin Pharmacother. 2008;9(13):2317-25.
13. Sillem M. Yasminelle((R)): a new low-dose combined oral contraceptive containing drospirenone. Womens Health (Lond Engl). 2006;2(4):551-9.
14. Westhoff C, Clark CJ. Benign ovarian cysts in England and Wales and in the United States. Br J Obstet Gynaecol. 1992;99(4):329-32.
15. Schindler AE. Pathophysiology, diagnosis and treatment of endometriosis. Minerva Ginecol. 2004;56(5):419-35.
16. Adamson D. Endometriosis: traditional perspectives, current evidence and future possibilities. Int J Fertil Womens Med. 2001;46(3):151-68.
17. Haider Z, D'Souza R. Non-contraceptive benefits and risks of contraception. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):249-62.
18. Seracchioli R, Mabrouk M, Manuzzi L, Vicenzi C, Frasca C, Elmakky A, et al. Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis. Hum Reprod. 2009;24(11):2729-35.
19. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84(5):1375-87.
20. Vercellini P, Somigliana E, Vigano P, Abbiati A, Barbara G, Crosignani PG. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009;69(6):649-75.
21. Maia H, Jr., Casoy J, Correia T, Freitas L, Pimentel K, Athayde C. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol. 2006;22(10):547-51.
22. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed). 1986;293(6543):359-62.
23. Chiaffarino F, Parazzini F, La Vecchia C, Marsico S, Surace M, Ricci E. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol. 1999;106(8):857-60.
24. Burkman RT. Oral contraceptives: current status. Clin Obstet Gynecol. 2001;44(1):62-72.
25. Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol. 1990;43(11):1221-30.
26. Jorgensen C, Picot MC, Bologna C, Sany J. Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis. 1996;55(2):94-8.
27. Drossaers-Bakker KW, Zwinderman AH, van Zeben D, Breedveld FC, Hazes JM. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis. 2002;61(5):405-8.
28. Holmqvist ST, Hammar M, Lindblom AM, Brynhirdsen J. Age at onset of Multiple sclerosis is correlated to use of combined oral hormonal contraceptives and child birth before diagnosis. Fert Steril. 2010;94():2835-7.
29. Kuhl H, Birkhauser M, Mueck A, Neulen J, Thaler C, Kiesel L, et al. [Long-cycle treatment in oral contraception]. Ther Umsch. 2009;66(2):101-8.
30. Sulak P, Willis S, Kuehl T, Coffee A, Clark J. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache. 2007;47(1):27-37.
31. Williams JK. Noncontraceptive benefits of oral contraceptive use: an evidence-based approach. Int J Fertil Womens Med. 2000;45(3):241-7.
32. La FM, Ledger WL, Davidson JW, Howard DM, Jones GL. The effects of a third generation combined oral contraceptive pill on the classical singing voice. J Voice. 2007;21(6):754-61.
33. Mandhane PJ, Hanna SE, Inman MD, Duncan JM, Greene JM, Wang HY, et al. Changes in exhaled nitric oxide related to estrogen and progesterone during the menstrual cycle. Chest. 2009;136(5):1301-7.
34. Royal College of General Practitioners' Oral Contraception Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives.Royal College of General Practitioners' Oral Contraception Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet. 1977;1():624.
35. Brinton LA, Vessey MP, Flavel R, Yeates D. Risk factors for benign breast disease. Am J Epidemiol. 1981;113(3):203-14.
36. Siskind V, Green A, Bain C, Purdie D. Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology. 2000;11(2):106-10.
37. The reduction in risk of ovarian cancer associated with oralcontraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development.The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316(11):650-5.
38. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 2007;335(7621):651.
39. Lyon: WHO, IARC; 1999. 72 p. IARC Monographs on the evaluation of carcinogenic risk to humans. Hormonal contraception and postmenopausal hormonal therapy.
40. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8):894-901.
41. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95(3):385-9.
42. Beral V, Doll R, Hermon C, Peto R, Reeves G. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-14.
43. Schlesselman JJ. Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol. 1995;85(5 Pt 1):793-801.
44. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol. 2007;8(1):26-34.
45. Modugno F, Ness RB, Allen GO, Schildkraut JM, Davis FG, Goodman MT. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol. 2004;191(3):733-40.
46. Noncontraceptive health benefits of combined oral contraception. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11(5):513-25.
47. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10(4):277-84.
48. Xu WH, Xiang YB, Ruan ZX, Zheng W, Cheng JR, Dai Q, et al. Menstrual and reproductive factors and endometrial cancer risk: Results from a population-based case-control study in urban Shanghai. Int J Cancer. 2004;108(4):613-9.
49. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: a metaanalysis. Br J Cancer. 2001;84(5):722-7.
50. Furner SE, Davis FG, Nelson RL, Haenszel W. A case-control study of large bowel cancer and hormone exposure in women. Cancer Res. 1989;49(17):4936-40.
51. Schindler AE. Long-term use of progestogens: colon adenoma and colon carcinoma. Gynecol Endocrinol. 2007;23:42-4.
52. Weiss NS, Daling JR, Chow WH. Incidence of cancer of the large bowel in women in relation to reproductive and hormonal factors. J Natl Cancer Inst. 1981;67(1):57-60.
53. Britt K, Short R. The plight of nuns: hazards of nulliparity. Lancet. 2012;379(9834):2322-3.